Follows people with multiple sclerosis to study early signs and digital monitoring
Collects data and samples from adults with multiple sclerosis to study early disease signs.
Plain-language title generated from the registry record
Registry title: Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
Key facts
- Where
- Basel, SwitzerlandSee the site
Where in Switzerland
- Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB)Basel, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT06526364
- Record updated
- 26 December 2025
- Original description
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.Read full original descriptionShow less
Clinnova-MS: a Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-Regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care (Switzerland)
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as well as (ii) to investigate digital biomarkers allowing the continuous clinical monitoring of those patients.
Inclusion: Age ≥18; Participants are willing and able to comply with the protocol, including undergoing data and samples collection as well as study visits and examinations; Signed informed consent form; In possession of a Healios+Me app compatible smartphone (iOS/Android); Corrected close visual acuity of ≥0.5; Hand motor skills sufficient for using a smartphone; Ability to follow the study procedures; Diagnosed with MS according to the revised McDonald criteria 2017, all clinical forms inclusive (clinically isolated syndrome, RRMS, SPMS, PPMS) AND early disease stages (< 3 years) OR transitioning phase to progressive disease as evaluated based on Expanded Disability Status Scale (EDSS); Enrolled in the SMSC at University Hospital Basel; There are no specific exclusion criteria.